Skip to main content
SpringerLink
Log in

Adenocarcinoma of the Esophagus and Cardia: A Review of the Disease and Its Treatment

  • Educational Review
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Over the past 50 years there has been a remarkable change in the epidemiology of esophageal cancer. Previously rare, adenocarcinoma of the esophagus and gastroesophageal junction is now the most common esophageal cancer, and in the United States the incidence is increasing faster than that of any other malignancy. Surveillance in patients with Barrett’s esophagus is identifying adenocarcinoma at an earlier, more curable stage in many patients, and at the same time new endoscopic and surgical options are available for the therapy of these localized tumors.

Methods

This article is a review of the epidemiology, diagnosis, staging, and treatment options for esophageal and gastroesophageal junction adenocarcinoma.

Results

The epidemiology, prognosis, patterns of lymphatic metastasis, and survival for esophageal and gastroesophageal junction adenocarcinoma suggest that these tumors are similar. New options for therapy, as well as the results of surgical resection with and without chemoradiotherapy, are reviewed.

Conclusions

Surveillance programs for Barrett’s are identifying patients with early, curable adenocarcinoma of the esophagus or gastroesophageal junction. Therapy for more advanced tumors hinges on local control of the disease and the eradication of systemic metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Armstrong RA, Blalock JB, Carrera G. Adenocarcinoma of the middle third of the esophagus arising from ectopic gastric mucosa. J Thorac Surg 1959;37:398–403

    Article  CAS  PubMed  Google Scholar 

  2. Hewlett A. The superficial glands of the esophagus. J Exp Med 1900;5:319

    Article  Google Scholar 

  3. Blot WJ, Devesa SS, Kneller RW, Fraumeni JFJ. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287–9

    Article  CAS  PubMed  Google Scholar 

  4. Kubo A, Corley DA. Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States. Am J Gastroenterol 2004;99:582–8

    Article  PubMed  Google Scholar 

  5. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142–6

    Article  PubMed  Google Scholar 

  6. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049–53

    Article  CAS  PubMed  Google Scholar 

  7. Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001;92:549–55

    Article  CAS  PubMed  Google Scholar 

  8. Kubo A, Corley DA. Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer 2002;95:2096–102

    Article  PubMed  Google Scholar 

  9. Botterweck AA, Schouten LJ, Volovics A, et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000;29:645–54

    Article  CAS  PubMed  Google Scholar 

  10. El-Serag HB. The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am 2002; 31:421–40

    Article  PubMed  Google Scholar 

  11. El-Serag HB, Mason AC, Petersen N, Key CR. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 2002;50:368–72

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Chen X, Yang CS. Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis 2001;22:1119–29

    Article  CAS  PubMed  Google Scholar 

  13. Cameron AJ. Epidemiology of Barrett’s esophagus and adenocarcinoma. Dis Esophagus 2002;15:106–8

    Article  CAS  PubMed  Google Scholar 

  14. Siewert RJ, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000;232:353–61

    Article  Google Scholar 

  15. Dolan K, Sutton R, Walker SJ, et al. New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology. Br J Cancer 1999;80:834–42

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90:150–5

    Article  CAS  PubMed  Google Scholar 

  17. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825–31

    Article  CAS  PubMed  Google Scholar 

  18. Mendes de Almeida JC, Chaves P, Pereira AD, Altorki NK. Is Barrett’s esophagus the precursor of most adenocarcinomas of the esophagus and cardia? A biochemical study. Ann Surg 1997;226:725–33; discussion 733–5

    Article  Google Scholar 

  19. Ruol A, Parenti A, Zaninotto G, et al. Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia. Cancer 2000;88:2520–8

    Article  CAS  PubMed  Google Scholar 

  20. Ireland AP, Shibata DK, Chandrasoma P, et al. Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia. Ann Surg 2000;231:179–87

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Lord RV, Tsai PI, Danenberg KD, et al. Retinoic acid receptor-alpha messenger RNA expression is increased and retinoic acid receptor-gamma expression is decreased in Barrett’s intestinal metaplasia, dysplasia, adenocarcinoma sequence. Surgery 2001;129:267–76

    Article  CAS  PubMed  Google Scholar 

  22. Sarbia M, Geddert H, Klump B, et al. Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract. Int J Cancer 2004;111:224–8

    Article  CAS  PubMed  Google Scholar 

  23. Nigro JJ, DeMeester SR, Hagen JA, et al. Node status in transmural esophageal adenocarcinoma and outcome after en bloc esophagectomy. J Thorac Cardiovasc Surg 1999;117:960–8

    Article  CAS  PubMed  Google Scholar 

  24. Wijnhoven BPL, Siersema PD, Hop WCJ, et al. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Br J Surg 1999;86:529–35

    Article  CAS  PubMed  Google Scholar 

  25. Freedman J, Ye W, Naslund E, Lagergren J. Association between cholecystectomy and adenocarcinoma of the esophagus. Gastroenterology 2001;121:548–53

    Article  CAS  PubMed  Google Scholar 

  26. DeMeester SR, DeMeester TR. Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy. Ann Surg 2000;231:303–21

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Vaughan TL, Farrow DC, Hansten PD, et al. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev 1998;7:749–56

    CAS  PubMed  Google Scholar 

  28. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer (review). Semin Oncol 1999;26(5 Suppl 15):2–8

    CAS  PubMed  Google Scholar 

  29. Lagergren J, Bergstrom R, Adami HO, Nyren O. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 2000;133:165–75

    Article  CAS  PubMed  Google Scholar 

  30. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999;130:883–90

    Article  CAS  PubMed  Google Scholar 

  31. Brown LM, Swanson CA, Gridley G, et al. Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst 1995;87:104–9

    Article  CAS  PubMed  Google Scholar 

  32. Gammon MD, Schoenberg JB, Ahsan H, et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1997;89:1277–84

    Article  CAS  PubMed  Google Scholar 

  33. Brown LM, Silverman DT, Pottern LM, et al. Adenocarcinoma of the esophagus and esophagogastric junction in white men in the United States: alcohol, tobacco, and socioeconomic factors. Cancer Causes Control 1994;5:333–40

    Article  CAS  PubMed  Google Scholar 

  34. Kabat GC, Ng SK, Wynder EL. Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia. Cancer Causes Control 1993;4:123–32

    Article  CAS  PubMed  Google Scholar 

  35. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7:97–102

    CAS  PubMed  Google Scholar 

  36. Chow WH, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998;58:588–90

    CAS  PubMed  Google Scholar 

  37. Chow W-H, Finkle WD, McLaughlin JK, et al. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995;274:474–7

    Article  CAS  PubMed  Google Scholar 

  38. Romero Y, Cameron AJ, Locke GR, et al. Familial aggregation of gastroesophageal reflux in patients with Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology 1997;113:1449–56

    Article  CAS  PubMed  Google Scholar 

  39. Lagergren J, Ye W, Lindgren A, Nyren O. Heredity and risk of cancer of the esophagus and gastric cardia. Cancer Epidemiol Biomarkers Prev 2000;9:757–60

    CAS  PubMed  Google Scholar 

  40. Dhillon PK, Farrow DC, Vaughan TL, et al. Family history of cancer and risk of esophageal and gastric cancers in the United States. Int J Cancer 2001;93:148–52

    Article  CAS  PubMed  Google Scholar 

  41. Solaymani-Dodaran M, Logan R, West J, et al. Risk of oesophageal cancer in Barrett’s oesophagus and gastro-oesophageal reflux. Gut 2004;53:1070–4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Rudolph RE, Vaughan TL, Storer BE, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000;132:612–20

    Article  CAS  PubMed  Google Scholar 

  43. Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett’s oesophagus in Olmsted County, Minnesota. Gut 2001;48:304–9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. van Blankenstein M, Looman , Johnston B, Caygill CP. Age and sex distribution of the prevalence of Barrett’s esophagus found in a primary referral endoscopy center. Am J Gastroenterol 2005;100:568–76

    Article  PubMed  Google Scholar 

  45. Goldblum JR. The significance and etiology of intestinal metaplasia of the esophagogastric junction. Ann Diagn Pathol 2002;6:67–73

    Article  PubMed  Google Scholar 

  46. Goldblum JR, Richter JE, Vaezi M, et al. Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa. Am J Gastroenterol 2002;97:302–11

    Article  PubMed  Google Scholar 

  47. DeMeester SR, Wickramasinghe K, Lord RV, et al. Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett’s esophagus. Am J Gastroenterol 2002;97:2514–23

    Article  PubMed  Google Scholar 

  48. Balaji NS, DeMeester SR, Wickramasinghe K, et al. Etiology of intestinal metaplasia at the gastroesophageal junction: reflux, H. pylori infection, or both? Surg Endosc 2003;17:43–8

    Article  CAS  PubMed  Google Scholar 

  49. Bowrey DJ, Clark GW, Williams GT. Patterns of gastritis in patients with gastro-oesophageal reflux disease. Gut 1999;45:798–803

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Couvelard A, Cauvin J-M, Goldfain D, et al. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology. Gut 2001;49:761–6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Peters JH, Clark GW, Ireland AP, et al. Outcome of adenocarcinoma arising in Barrett’s esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994;108:813–21; discussion 821–2

    Article  CAS  PubMed  Google Scholar 

  52. Stein HJ, Siewert JR. Improved prognosis of resected esophageal cancer. World J Surg 2004;28:520–5

    Article  PubMed  Google Scholar 

  53. Nigro JJ, Hagen JA, DeMeester TR, et al. Occult esophageal adenocarcinoma: extent of disease and implication for effective therapy. Ann Surg 1999;230:433–40

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Heidemann J, Schilling MK, Schmassmann A, et al. Accuracy of endoscopic ultrasonography in preoperative staging of esophageal carcinoma. Dig Surg 2000;17:219–24

    Article  CAS  PubMed  Google Scholar 

  55. Flamen P, Lerut A, Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000;18:3202–10

    Article  CAS  PubMed  Google Scholar 

  56. Wallace MB, Nietert PJ, Earle C, et al. An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann Thorac Surg 2002;74:1026–32

    Article  PubMed  Google Scholar 

  57. Kato H, Kuwano H, Nakajima M, et al. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 2002;184:279–83

    Article  PubMed  Google Scholar 

  58. Krasna MJ, Flowers JL, Attar S, McLaughlin J. Combined thoracoscopic/laparoscopic staging of esophageal cancer. J Thorac Cardiovasc Surg 1996;111:800–6; discussion 806–7

    Article  CAS  PubMed  Google Scholar 

  59. Freeman RK, Wait MA. Port site metastasis after laparoscopic staging of esophageal carcinoma. Ann Thorac Surg 2001;71:1032–4

    Article  CAS  PubMed  Google Scholar 

  60. Rice TW, Blackstone EH, Goldblum JR, et al. Superficial adenocarcinoma of the esophagus. J Thorac Cardiovasc Surg 2001;122:1077–90

    Article  CAS  PubMed  Google Scholar 

  61. Korst RJ, Rusch VW, Venkatraman E, et al. Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg 1998;115:660–9; discussion 669–70

    Article  CAS  PubMed  Google Scholar 

  62. Rice TW, Zuccaro G Jr, Adelstein DJ, et al. Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg 1998;65:787–92

    Article  CAS  PubMed  Google Scholar 

  63. Hagen J, DeMeester S, Peters J, et al. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg 2001;234:520–31

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Ellis FH Jr, Heatley GJ, Balogh K. Proposal for improved staging criteria for carcinoma of the esophagus and cardia. Eur J Cardiothorac Surg 1997;12:361–4; discussion 364–5

    Article  PubMed  Google Scholar 

  65. Holscher AH, Bollschweiler E, Bumm R, et al. Prognostic factors of resected adenocarcinoma of the esophagus. Surgery 1995;118:845–55

    Article  CAS  PubMed  Google Scholar 

  66. Ellis FH Jr, Heatley GJ, Krasna MJ, et al. Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. J Thorac Cardiovasc Surg 1997;113:836–46; discussion 846–8

    Article  PubMed  Google Scholar 

  67. Kawakami K, Brabender J, Lord RV, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000;92:1805–11

    Article  CAS  PubMed  Google Scholar 

  68. Schneider PM, Stoeltzing O, Roth JA, et al. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett’s esophagus. Clin Cancer Res 2000;6:3153–8

    CAS  PubMed  Google Scholar 

  69. Aloia TA, Harpole DH Jr, Reed CE, et al. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 2001;72:859–66

    Article  CAS  PubMed  Google Scholar 

  70. Samejima R, Kitajima Y, Yunotani S, Miyazaki K. Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma. Anticancer Res 1999;19:5515–21

    CAS  PubMed  Google Scholar 

  71. Heeren PA, Kloppenberg FW, Hollema H, et al. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus. Anticancer Res 2004;24:2579–83

    PubMed  Google Scholar 

  72. O’Sullivan GC, Sheehan D, Clarke A, et al. Micrometastases in esophagogastric cancer: high detection rate in resected rib segments. Gastroenterology 1999;116:543–8

    Article  PubMed  Google Scholar 

  73. Bonavina L, Soligo D, Quirici N, et al. Bone marrow-disseminated tumor cells in patients with carcinoma of the esophagus or cardia. Surgery 2001;129:15–22

    Article  CAS  PubMed  Google Scholar 

  74. Nigro JJ, Hagen JA, DeMeester TR, et al. Prevalence and location of nodal metastases in distal esophageal adenocarcinoma confined to the wall: implications for therapy [see comments]. J Thorac Cardiovasc Surg 1999;117:16–23; discussion 23–5

    Article  CAS  PubMed  Google Scholar 

  75. van Sandick JW, van Lanschot JJ, ten Kate FJ, et al. Pathology of early invasive adenocarcinoma of the esophagus or esophagogastric junction: implications for therapeutic decision making. Cancer 2000;88:2429–37

    Article  PubMed  Google Scholar 

  76. Altorki NMD, Skinner DMD. Should en bloc esophagectomy be the standard of care for esophageal carcinoma? Ann Surg 2001;234:581–7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Ando N, Ozawa S, Kitagawa Y, et al. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000;232:225–32

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161–7

    Article  CAS  PubMed  Google Scholar 

  79. Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992;16:1104–9; discussion 1110

    Article  CAS  PubMed  Google Scholar 

  80. Akiyama H, Tsurumaru M, Kawamura T, Ono Y. Esophageal stripping with preservation of the vagus nerve. Int Surg 1982;67:125–8

    CAS  PubMed  Google Scholar 

  81. Banki F, Mason RJ, DeMeester SR, et al. Vagal-sparing esophagectomy: a more physiologic alternative. Ann Surg 2002;236:324–35; discussion 335–6

    Article  PubMed  PubMed Central  Google Scholar 

  82. May A, Gunter E, Roth F, et al. Accuracy of staging in early esophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial. Gut 2004;53:634–40

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Maish MS, DeMeester SR. Endoscopic mucosal resection as a staging technique to determine the depth of invasion of esophageal adenocarcinoma. Ann Thorac Surg 2004;78:1777–82

    Article  PubMed  Google Scholar 

  84. Urba S, Orringer M, Turisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305–13

    Article  CAS  PubMed  Google Scholar 

  85. Hulscher JB, van Sandick JW, Tijssen JG, et al. The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg 2000;191:143–8

    Article  CAS  PubMed  Google Scholar 

  86. Law SY, Fok M, Wong J. Pattern of recurrence after oesophageal resection for cancer: clinical implications. Br J Surg 1996;83:107–11

    Article  CAS  PubMed  Google Scholar 

  87. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662–9

    Article  PubMed  Google Scholar 

  88. Sihvo EI, Luostarinen ME, Salo JA. Fate of patients with adenocarcinoma of the esophagus and the esophagogastric junction: a population-based analysis. Am J Gastroenterol 2004;99:419–24

    Article  PubMed  Google Scholar 

  89. Orringer MB, Marshall B, Iannettoni MD. Transhiatal esophagectomy: clinical experience and refinements. Ann Surg 1999;230:392–400; discussion 400–3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Johansson J, DeMeester TR, Hagen JA, et al. En bloc vs transhiatal esophagectomy for stage T3 N1 adenocarcinoma of the distal esophagus. Arch Surg 2004;139:627–31; discussion 631–3

    Article  PubMed  Google Scholar 

  91. Luketich JD, Alvelo-Rivera M, Buenaventura PO, et al. Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg 2003;238:486–94; discussion 494–5

    Article  PubMed  PubMed Central  Google Scholar 

  92. Branicki FJ, Law SY, Fok M, et al. Quality of life in patients with cancer of the esophagus and gastric cardia: a case for palliative resection. Arch Surg 1998;133:316–22

    Article  CAS  PubMed  Google Scholar 

  93. Swisher SG, Deford L, Merriman KW, et al. Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg 2000;119:1126–32

    Article  CAS  PubMed  Google Scholar 

  94. Dimick JB, Cattaneo SM, Lipsett PA, et al. Hospital volume is related to clinical and economic outcomes of esophageal resection in Maryland. Ann Thorac Surg 2001;72:334–9; discussion 339–41

    Article  CAS  PubMed  Google Scholar 

  95. Patti MG, Corvera CU, Glasgow RE, Way LW. A hospital’s annual rate of esophagectomy influences the operative mortality rate. J Gastrointest Surg 1998;2:186–92

    Article  CAS  PubMed  Google Scholar 

  96. Karl RC, Schreiber R, Boulware D, et al. Factors affecting morbidity, mortality, and survival in patients undergoing Ivor Lewis esophagogastrectomy. Ann Surg 2000;231:635–43

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Johansson J, Walther B. Clinical outcome and long-term survival rates after esophagectomy are not determined by age over 70 years. J Gastrointest Surg 2000;4:55–62

    Article  CAS  PubMed  Google Scholar 

  98. Kirby JD. Quality of life after oesophagectomy: the patients’ perspective. Dis Esophagus 1999;12:168–71

    Article  CAS  PubMed  Google Scholar 

  99. Blazeby JM, Farndon JR, Donovan J, Alderson D. A prospective longitudinal study examining the quality of life of patients with esophageal carcinoma. Cancer 2000;88:1781–7

    Article  CAS  PubMed  Google Scholar 

  100. de Boer AG, van Lanschot JJ, van Sandick JW, et al. Quality of life after transhiatal compared with extended transthoracic resection for adenocarcinoma of the esophagus. J Clin Oncol 2004;22:4202–8

    Article  PubMed  Google Scholar 

  101. Headrick JR, Nichols FC III, Miller DL, et al. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg 2002;73:1697–702; discussion 1702–3

    Article  PubMed  Google Scholar 

  102. Gawad KA, Hosch SB, Bumann D, et al. How important is the route of reconstruction after esophagectomy: a prospective randomized study. Am J Gastroenterol 1999;94:1490–6

    Article  CAS  PubMed  Google Scholar 

  103. DeMeester SR. Colon interposition following esophagectomy. Dis Esophagus 2001;14:169–72

    Article  CAS  PubMed  Google Scholar 

  104. Briel JW, Tamhankar AP, Hagen JA, et al. Prevalence and risk factors for ischemia, leak, and stricture of esophageal anastomosis: gastric pull-up versus colon interposition. J Am Coll Surg 2004;198:536–41; discussion 541–2

    Article  PubMed  Google Scholar 

  105. Ludwig DJ, Thirlby RC, Low DE. A prospective evaluation of dietary status and symptoms after near-total esophagectomy without gastric emptying procedure. Am J Surg 2001;181:454–8

    Article  CAS  PubMed  Google Scholar 

  106. Velanovich V. Esophagogastrectomy without pyloroplasty. Dis Esophagus 2003;16:243–5

    Article  CAS  PubMed  Google Scholar 

  107. Urschel JD, Blewett CJ, Young JE, et al. Pyloric drainage (pyloroplasty) or no drainage in gastric reconstruction after esophagectomy: a meta-analysis of randomized controlled trials. Dig Surg 2002;19:160–4

    Article  PubMed  Google Scholar 

  108. Whooley BP, Law S, Alexandrou A, et al. Critical appraisal of the significance of intrathoracic anastomotic leakage after esophagectomy for cancer. Am J Surg 2001;181:198–203

    Article  CAS  PubMed  Google Scholar 

  109. Lerut T, Coosemans W, Decker G, et al. Anastomotic complications after esophagectomy. Dig Surg 2002;19:92–8

    Article  CAS  PubMed  Google Scholar 

  110. Crestanello JA, Deschamps C, Cassivi SD, et al. Selective management of intrathoracic anastomotic leak after esophagectomy. J Thorac Cardiovasc Surg 2005;129:254–60

    Article  PubMed  Google Scholar 

  111. Dresner SM, Griffin SM, Wayman J, et al. Human model of duodenogastro-oesophageal reflux in the development of Barrett’s metaplasia. Br J Surg 2003;90:1120–8

    Article  CAS  PubMed  Google Scholar 

  112. Lord RV, Wickramasinghe K, Johansson JJ, et al. Cardiac mucosa in the remnant esophagus after esophagectomy is an acquired epithelium with Barrett’s-like features. Surgery 2004;136:633–40

    Article  PubMed  Google Scholar 

  113. O’Riordan JM, Tucker ON, Byrne PJ, et al. Factors influencing the development of Barrett’s epithelium in the esophageal remnant postesophagectomy. Am J Gastroenterol 2004;99:205–11

    Article  PubMed  Google Scholar 

  114. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett’s esophagus: follow-up in 100 patients. Gastrointest Endosc 1999;49:1–7

    Article  CAS  PubMed  Google Scholar 

  115. Panjehpour M, Overholt BF, Haydek JM, Lee SG. Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett’s esophagus and effect of oral steroids on stricture formation. Am J Gastroenterol 2000;95:2177–84

    Article  CAS  PubMed  Google Scholar 

  116. Krishnadath KK, Wang KK, Taniguchi K, et al. Persistent genetic abnormalities in Barrett’s esophagus after photodynamic therapy. Gastroenterology 2000;119:624–30

    Article  CAS  PubMed  Google Scholar 

  117. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett’s esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003;58:183–8

    Article  PubMed  Google Scholar 

  118. Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of photodynamic therapy for treatment of Barrett’s esophagus with high grade dysplasia. Dig Dis Sci 2003;48:1273–83

    Article  PubMed  Google Scholar 

  119. Shimizu Y, Tsukagoshi H, Fujita M, et al. Long-term outcome after endoscopic mucosal resection in patients with esophageal squamous cell carcinoma invading the muscularis mucosae or deeper. Gastrointest Endosc 2002;56:387–90

    Article  PubMed  Google Scholar 

  120. Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett’s esophagus. Gastroenterology 2000;118:670–7

    Article  CAS  PubMed  Google Scholar 

  121. Buttar N, Nijhawan P, Krishnadath K, et al. Combined endoscopic mucosal resection (EMR) and photodynamic therapy (PDT) for esophageal neoplasia within Barrett’s esophagus. Gastroenterology 2000;118:A405

    Google Scholar 

  122. Roth JA, Pass HI, Flanagan MM, et al. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 1988;96:242–8

    Article  CAS  PubMed  Google Scholar 

  123. Law S, Fok M, Chow S, et al. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997;114:210–7

    Article  CAS  PubMed  Google Scholar 

  124. Schlag PM. Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. Arch Surg 1992;127:1446–50

    Article  CAS  PubMed  Google Scholar 

  125. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979–84

    Article  CAS  PubMed  Google Scholar 

  126. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001;91:2165–74

    Article  CAS  PubMed  Google Scholar 

  127. Medical Research Council Oesophageal Cancer Working Group. Sugical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial [see comment]. Lancet 2002;359:1727–33

    Article  Google Scholar 

  128. Gignoux M, Roussel A, Paillot B, et al. The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C. World J Surg 1987;11:426–32

    Article  CAS  PubMed  Google Scholar 

  129. Wang M, Gu XZ, Yin WB, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients. Int J Radiat Oncol Biol Phys 1989;16:325–7

    Article  CAS  PubMed  Google Scholar 

  130. Launois B, Delarue D, Campion JP, Kerbaol M. Preoperative radiotherapy for carcinoma of the esophagus. Surg  Gynecol Obstet 1981;153:690–2

    CAS  PubMed  Google Scholar 

  131. Arnott SJ, Duncan W, Kerr GR, et al. Low dose preoperative radiotherapy for carcinoma of the oesophagus: results of a randomized clinical trial. Radiother Oncol 1992;24:108–13

    Article  CAS  PubMed  Google Scholar 

  132. Arnott SJ, Duncan W, Gignoux M, et al. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). Int J Radiat Oncol Biol Phys 1998;41:579–83

    Article  CAS  PubMed  Google Scholar 

  133. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial [see comment]. Lancet Oncology 2005; 6:659–68

    Article  PubMed  Google Scholar 

  134. Le Prise E, Etienne PL, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994;73:1779–84

    Article  CAS  PubMed  Google Scholar 

  135. Apinop , Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 1994;41:391–3

    CAS  PubMed  Google Scholar 

  136. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma (erratum appears in N Engl J Med 1999;341:384). N Engl J Med 1996;335:462–7

    Article  CAS  PubMed  Google Scholar 

  137. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004;53:925–30

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Smalley SR, Gunderson LL, Reddy EK, Williamson S. Radiotherapy alone in esophageal carcinoma: current management and future directions of adjuvant, curative and palliative approaches. Semin Oncol 1994;21:467–73

    CAS  PubMed  Google Scholar 

  139. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623–7

    Article  CAS  PubMed  Google Scholar 

  140. Chidel MA, Rice TW, Adelstein DJ, et al. Resectable esophageal carcinoma: local control with neoadjuvant chemotherapy and radiation therapy. Radiology 1999;213:67–72

    Article  CAS  PubMed  Google Scholar 

  141. Keller SM, Ryan LM, Coia LR, et al. High dose chemoradiotherapy followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction: results of a phase II study of the Eastern Cooperative Oncology Group. Cancer 1998;83:1908–16

    Article  CAS  PubMed  Google Scholar 

  142. Jiao X, Krasna MJ, Sonett J, et al. Pretreatment surgical lymph node staging predicts results of trimodality therapy in esophageal cancer. Eur J Cardiothorac Surg 2001;19:880–6

    Article  CAS  PubMed  Google Scholar 

  143. Lehnert T. Multimodal therapy for squamous carcinoma of the oesophagus. Br J Surg 1999;86:727–39

    Article  CAS  PubMed  Google Scholar 

  144. Levard H, Pouliquen X, Hay JM, et al. 5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research. Eur J Surg 1998;164:849–57

    Article  CAS  PubMed  Google Scholar 

  145. Ando N, Iizuka T, Kakegawa T, et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997;114:205–9

    Article  CAS  PubMed  Google Scholar 

  146. Teniere P, Hay JM, Fingerhut A, Fagniez PL. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet 1991;173:123–30

    CAS  PubMed  Google Scholar 

  147. Zieren HU, Muller JM, Jacobi CA, et al. Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg 1995;19:444–9

    Article  CAS  PubMed  Google Scholar 

  148. Fok M, Sham JS, Choy D, et al. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 1993;113:138–47

    CAS  PubMed  Google Scholar 

  149. Bedard EL, Inculet RI, Malthaner RA, et al. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer 2001;91:2423–30

    Article  CAS  PubMed  Google Scholar 

  150. Rice TW, Adelstein DJ, Chidel MA, et al. Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. J Thorac Cardiovasc Surg 2003;126:1590–6

    Article  PubMed  Google Scholar 

  151. Newaishy GA, Read GA, Duncan W, Kerr GR. Results of radical radiotherapy of squamous cell carcinoma of the oesophagus. Clin Radiol 1982;33:347–52

    Article  CAS  PubMed  Google Scholar 

  152. Beatty JD, DeBoer G, Rider WD. Carcinoma of the esophagus: pretreatment assessment, correlation of radiation treatment parameters with survival, and identification and management of radiation treatment failure. Cancer 1979;43:2254–67

    Article  CAS  PubMed  Google Scholar 

  153. Sun DR. Ten-year follow-up of esophageal cancer treated by radical radiation therapy: analysis of 869 patients. Int J Radiat Oncol Biol Phys 1989;16:329–34

    Article  CAS  PubMed  Google Scholar 

  154. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593–8

    Article  CAS  PubMed  Google Scholar 

  155. Gaspar LE, Winter K, Kocha WI, et al. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report. Cancer 2000;88:988–95

    Article  CAS  PubMed  Google Scholar 

  156. Jani AB, Connell PP, Vesich VJ, et al. Analysis of the role of adjuvant chemotherapy for invasive carcinoma of the esophagus. Am J Clin Oncol 2000;23:554–8

    Article  CAS  PubMed  Google Scholar 

  157. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309–16

    Article  CAS  PubMed  Google Scholar 

  158. Johnston PG, Lenz HJ, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407–12

    CAS  PubMed  Google Scholar 

  159. Park DJ, Stoehlmacher J, Lenz HJ. Tailoring chemotherapy in advanced colorectal cancer. Curr Opin Pharmacol 2003;3:378–85

    Article  CAS  PubMed  Google Scholar 

  160. Juhasz A, Frankel P, Cheng C, et al. Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products. J Clin Lab Anal 2003;17:184–94

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  161. McNamara DA, Harmey JH, Walsh TN, et al. Significance of angiogenesis in cancer therapy (published erratum appears in Br J Surg 1998;85:1449; review). Br J Surg 1998;85:1044–55

    Article  CAS  PubMed  Google Scholar 

  162. Zambon A, Mandruzzato S, Parenti A, et al. MAGE, BAGE, and GAGE gene expression in patients with esophageal squamous cell carcinoma and adenocarcinoma of the gastric cardia. Cancer 2001;91:1882–8

    Article  CAS  PubMed  Google Scholar 

  163. Eliakim R, Yassin K, Shlomi I, et al. A novel diagnostic tool for detecting oesophageal pathology: the PillCam oesophageal video capsule. Aliment Pharmacol Ther 2004; 20:1083–9

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiothoracic Surgery, The University of Southern California, Keck School of Medicine, 1510 San Pablo Street, Suite 514, Los Angeles, California, 90033

    Steven R. DeMeester MD

Authors
  1. Steven R. DeMeester MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven R. DeMeester MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

DeMeester, S.R. Adenocarcinoma of the Esophagus and Cardia: A Review of the Disease and Its Treatment. Ann Surg Oncol 13, 12–30 (2006). https://doi.org/10.1245/ASO.2005.12.025

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2005.12.025

Keywords

Search

Navigation